Recent Developments in Adrenergic Receptor Polymorphisms in Essential Hypertension

Objective: This review's goal is to provide an overview of the most recent data about the genetic foundations of adrenergic receptor polymorphisms in connection with essential hypertension (EH). Since EH is idiopathic, research is centered on its genetic underpinnings and significant interindividual differences in response to various therapies. Polymorphisms as an important element affecting individual disease susceptibility processes, are therefore, area of research interest for especially for genes that modulate variety of metabolic processes Methods: A comprehensive, systematic literature search was conducted using a number of databases, including PubMed, Google Scholar, and Web of Science (WOS). Recent research in the field that looked into the connections between blood pressure, heart disease, hypertension, and vascular problems was taken into account. Only studies with common polymorphisms, uniform criteria and statistics were included in order to assess consistent information and provide a broad perspective. Results: There are a limited number of studies in the literature after 2010 related to the adrenergic system polymorphisms, blood pressure, and/or essential hypertension. Genome-wide studies and meta-analyses reveal that there are several variants whose roles were supported by independent studies. ADRA1 Arg347Cys (rs1048101), ADRA2 C-1291G variant (rs1800544), ADRB1 Arg38Gly, ADRB2 Arg46Gly and ADRB3 Trp64ARg (rs4994) can be counted as major polymorphisms with their role verified by multiple researches. Conclusion: Despite being supported by numerous research, the association between adrenergic system polymorphisms and essential hypertension cannot be conclusively established due to the unpredictability of study patient numbers, side effects, and inconsistent findings. Larger and more controlled population-based studies are required to provide a clear picture of the disease's variability and treatment responses.